8 November 2018
Report from Extraordinary General Meeting of Immunicum AB (publ) on 8 November 2018
The Extraordinary General Meeting (the “EGM”) of Immunicum AB (publ), reg. no 556629-1786, was held today. The EGM resolved to approve both the Board of Directors’ resolution on a directed share issue and to approve the Board of Directors’ resolution on a new issue of shares with preferential rights for the shareholders. For more detailed information regarding the contents of the resolutions, refer to the complete proposals, which have previously been published and are available on the company’s website, www.immunicum.com.
Resolution on approval of directed new issue of shares
The EGM resolved to approve the Board of Directors’ resolution of 16 October 2018 on a new issue of shares with deviation from the shareholders’ preferential rights.
The directed issue entails that the company’s share capital shall be increased with a maximum amount of SEK 1,045,779.40 by issue of at most 20,915,588 new shares. The subscription price is SEK 8.50 per share and is deemed to be in accordance with the market. At full subscription the company will be provided with an amount of approximately MSEK 178 (before issue expenses).
Resolution on approval of new issue of shares (rights issue)
The EGM resolved to approve the Board of Directors’ resolution of 16 October 2018 on a new issue of shares with preferential rights for the shareholders.
The Rights Issue entails that the company’s share capital shall be increased with a maximum amount of 1,019,170.60 SEK by issue of at most 20,383,412 new shares with preferential rights for the company’s existing shareholders. The subscription price is SEK 8.50 per share. At full subscription the company will be provided with an amount of approximately MSEK 173 (before issue expenses).
Shareholders in the company have preferential right to subscribe for shares whereupon one (1) existing share in the company entitles to one (1) subscription right and five (5) subscription rights entitle to subscribe for two (2) new shares. New shares may also be subscribed for without subscription rights.
The record date for obtaining subscription rights and the right to participate in the new issue of shares with preferential rights is on Wednesday, 21 November 2018. Subscription of shares, both with and without the exercise of subscription rights, is to take place during the period starting on Monday, 26 November 2018 up to and including Monday, 10 December 2018.
The information in this press release is disclosed pursuant to the rules for companies listed on Nasdaq Stockholm. The information was released for public disclosure through the agency of the company’s contact person on 8 November, 2018 at 4.30 pm CET.
For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
Michaela Gertz, CFO, Immunicum
Telephone: +46 70 926 17 75
Gretchen Schweitzer and Joanne Tudorica
Telephone: +49 172 861 8540
About Immunicum AB (publ)
Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com